Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin

> Dr. Christy White Dr. Sangho Yu

### **MEETING MINUTES**

Thursday, August 14<sup>th</sup>, 2025 2:00 PM – B2001

Institution	Pennington Biomedical Research Center
	Baton Rouge, LA
Meeting Date	Thursday, August 14 <sup>th</sup> , 2025
Meeting Time	2:04 PM – 2:44 PM
Meeting Type	In person meeting
IBC Members	1. Dr. Jason Collier, (Chair)
Present	2. Dr. Christy White (Safety Officer)
	3. Dr. Diana Coulon (Animal expert)
	4. Dr. Timothy Heden
	5. Dr. Stefany Primeaux
	6. Dr. Erik Westin
	7. Dr. Sangho Yu
	8. Leonard Ezell (Community Non-affiliated Member)

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin Dr. Christy White

	9. Jennifer Strickland (Community Non-affiliated Member)
IBC Members Absent	1. Dr. Steven Hennigar
	2. Dr. Krisztian Stadler, (Vice Chair)
	3. Abigail Fish (Non-Voting Member)
Quorum	Present
Other Individuals in Attendance	N/A
Call to Order	2:04 pm
Conflicts of Interest	The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.
Review and approval of previous meeting minutes	July 10th, 2025
	Motion: Dr. Sango Yu
	Second: Dr. Stefany Primeaux
	All in Favor 9/9

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin Dr. Christy White

Review of Prior Business	N/A
New IBC Registrations and A	mendments for Review
PI Name(s)	Timothy Heden PhD.
Registration Number/Title	New Registration: R2506
	Molecular Metabolism Lab IBC Registration
Project Overview	The primary goal of projects performed in the molecular metabolism lab are
	to develop a better understanding of how metabolism becomes dysfunctional
	in metabolic diseases, such as cancer, obesity, and diabetes, as well as
	genetic diseases, such as glycogen storage diseases and lysosomal storage
	diseases, and to test novel treatments for these diseases. We hypothesize
	rewired metabolism alters gene expression patterns to promote metabolic
	and genetic diseases. We utilize a combination of nutritional, exercise, or
	genetic therapies in cells, mice, or humans to test our hypothesis.
NIH Guidelines	Section III-D-1-a
Section	Section III-D-3-a
	Section III-D-4-a

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin Dr. Christy White

	Section III-E-3-a
Risk Assessment and Discussion	The Risk Group 1 and Risk Group 2 viral vectors used are both replication incompetent. Human cell lines carry the risk of bloodborne pathogens. Bacterial cells are not known to cause disease in immunocompetent individuals. Risk will be minimized through training, engineering controls and proper PPE use.
Training	All required training courses are complete for all lab staff listed in the registration.
Occupational Health Representative review (if applicable):	N/A
Biosafety Level Assignment	BSL-1 BSL-2 ABSL-1 BL1-N
IBC Vote	A motion was made and seconded to approve the registration pending changes or conditions to be met. All in favor 8/8 Abstaining: Tim Heden Conflicts of Interest: none

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin

Modifications Requested	1) Minor clarification requested on PPE use.
	2) Minor clarification requested on room locations.
	3) Clarification on source of virus and human samples requested.
	4) Completion of the microbial section requested.
	5) Information on transport of human tissues requested.
	6) Minor change requested in waste decontamination.
	7) Updating of room numbers and phone numbers on SOP requested.
	8) References to Risk Group 2 agent use in mice need to be removed.
Now IDC Degistrations and A	mandments for Davious
New IBC Registrations and A	mendments for Review
New IBC Registrations and A	mendments for Review
New IBC Registrations and A  PI Name(s)	Robert Kesterson
PI Name(s)	Robert Kesterson
PI Name(s)	Robert Kesterson
PI Name(s) Registration Number/Title	Robert Kesterson  Amendment: R2305  Cancer precision medicine laboratory
PI Name(s)	Robert Kesterson  Amendment: R2305

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin

	related genetic disorders by studying mutations found in patients with NF1 by creating gene copies (cDNA) of the affected gene and comparing functional differences compared to the normal gene. Cell lines and animal models that have been genetically modified to mimic the exact mutations found in patients are used.
	This amendment will add a biologically active RNA (antisense oligos) to be tested as a new therapeutic compound that will be expressed from a Risk Group 1 viral vector and injected via ICV or intrathecally to enrich distribution in a population of tumors found along the spinal cord.
NIH Guidelines Section	No change.
Risk Assessment and Discussion	No change in risk is apparent for employees. There may be some risk of antisense oligos concentrating in certain organs in the mice causing side effects.
Training	All required training courses are complete for all lab staff listed in the registration.
Occupational Health Representative review (if applicable):	N/A
Biosafety Level Assignment	No change.

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin

IBC Vote	A motion was made and seconded to approve the registration pending changes or conditions to
	be met. All in favor 8/8
	Abstaining: Erik Westin
	Conflicts of Interest: none
Modifications Requested	1) Requested to include information on what the new therapeutic is and how it differs from
	the previously approved Risk Group 1 viral vector.
	2) Include a risk assessment for antisense oligos.
New IBC Registrations and A	mendments for Review
PI Name(s)	Heike Muenzberg
Registration Number/Title	Amendment: R2301
	Dissection of central and peripheral signaling pathways that control energy homeostasis
Project Overview	The goal of the experiments under the original IBC registration is to examine neurons in the
	central and peripheral nervous system and their function to maintain energy balance. In order
	to identify the connectivity and function of select neurons the lab uses different viruses to either
	induce expression of a variety of genes or to remove expression of select genes. The

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin Dr. Christy White

Biosafety Level Assignment	No Change
Occupational Health Representative review (if applicable):	N/A
Training	All required training courses are complete for all lab staff listed in the registration.
Risk Assessment and Discussion	There is no change in risk and no additional safety practices required.
NIH Guidelines Section	No Change
	This amendment is adding the expression of a different reporter gene in a Risk Group 1 viral vector.
	<ul> <li>to express fluorescent proteins (=reporter genes) to visualize select neurons, their processes into distant brain sites and peripheral tissues</li> <li>to expressed receptors and ion channels that allow modulation of neuronal activity</li> <li>to delete gene expression in select neurons</li> </ul>

Dr. Diana Coulon Dr. Timothy Heden

Dr. Stephen Hennigar Dr. Abigal Fish (Non-Voting Member) Dr. Jason Collier, Chair Dr. Krisztian Stadler, Vice-Chair

Dr. Leonard Ezell, Community Representative Jennifer Strickland, Community Representative Dr. Chritopher Morrison, Responsible Official Dr. Stefany Primeaux Dr. Erik Westin

IBC Vote	A motion was made and seconded to approve the registration pending changes or conditions to
	be met. All in favor 9/9
	Abstaining: none
	Conflicts of Interest: none
Modifications Requested	1) The correction of two typos.
Other Business	
New member	Jennifer Strickland was introduced as a new member to replace outgoing member Ed Kuhnert.
SOP review	Urethane SOP was reviewed and updates approved.
Adjournment	The IBC Chair moved to adjourn the meeting at 2:44PM.
	Next Month's Meeting will be scheduled for September 11 <sup>th</sup> at 2 pm